Skyrizi® and Tegsedi® will be covered under the pharmacy benefit for Blue Cross' PPO and BCN HMOSM members, effective Oct. 8, 2020

We're changing how we cover Skyrizi and Tegsedi for our Blue Cross' PPO (commercial) and BCN HMO (commercial) members.

Beginning Oct. 8, 2020, Blue Cross' PPO and BCN HMO plans will no longer cover the following medications under the medical benefit. Instead, they'll be covered under the pharmacy benefit.

Coverage for these drugs is moving to the pharmacy benefit because the drugs can be safely and conveniently self-administered in the member's home.

These drugs will continue to require prior authorization and are available through pharmacies that dispense specialty drugs, including AllianceRx Walgreens Prime Specialty Pharmacy.

We'll contact any member who is affected by this change and advise them to talk to their doctor about prescribing these medications for purchase from a pharmacy.

Providers who administer these medications to their patients on or after Oct. 8, 2020, will be responsible for the cost.

Are there any changes to the management for these therapies?

There are no changes to the management of these therapies.

Submitting prior authorization requests

Providers can submit prior authorization requests for these drugs as follows:

List of requirements

To view requirements for Skyrizi, Tegsedi and other drugs covered under the pharmacy benefit, see the Blue Cross and BCN Prior authorization and step therapy coverage criteria (PDF) document. This document is available from the following pages on the this website.

For a list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross PPO (commercial) and BCN HMO (commercial) members (PDF) document.

Posted: October 2020
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network